Yu Mi Kang on the PCSK9 inhibitor Evolocumab & the FOURIER Trial, Neda Rasouli with insights on semaglutide in symptomatic peripheral artery disease & the STRIDE Trial, and more!

About this episode

The episode discusses the PCSK9 inhibitor Evolocumab and insights on semaglutide in peripheral artery disease, featuring expert guests.

Welcome to episode no. 35 (September 2025) of Diabetes Care "On Air"—a new and different way to bring the research published in Diabetes Care to life. Join co-hosts Alice Cheng, MD, FRCPC, and Michael Rickels, MD, MS, as they discuss the latest and greatest content in the September 2025 issue of Diabetes Care and beyond. 3:05 Alice is joined by Yu Mi Kang , MD, PhD, endocrinologist at Brigham and Women's Hospital and instructor at Harvard University in Boston. The discuss her article, "Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial," available for free at doi.org/10.2337/dc25-0942 . 14:10 Mike speaks with Neda Rasouli , MD, Professor of Medicine in the Division of Endocrinology, Metabolism, and Diabetes at the University of Anschutz Medical Campus. She shares insights from her article, "Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial," available for free at doi.org/10.2337/dc25-1082 . 27:20 In the "Diabetes Care Rapid Exchange," Alice and Mike wrap up the…

People in this episode

Hosts: Alice Cheng, Michael Rickels

Guests: Yu Mi Kang, Neda Rasouli

Topics covered

• PCSK9 inhibitor
• Evolocumab
• FOURIER Trial
• semaglutide
• peripheral artery disease
• STRIDE Trial
• Diabetes Care

Keywords

• Diabetes Care
• Evolocumab
• FOURIER Trial
• semaglutide
• peripheral artery disease
• STRIDE Trial
• Alice Cheng
• Michael Rickels

Mentioned in this episode

Organizations: Brigham and Women's Hospital, Harvard University, University of Anschutz Medical Campus

Books & works: Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial, Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial

More episodes of Diabetes Care "On Air"

• Lutz Heinemann on the challenges and opportunities of individualizing diabetes technology, Kathleen Dungan on hyperglycemia during acute pancreatitis and the progression to early-onset diabetes, plus a classic edition of "Rapid Exchange." · June 2, 2026 · 58 min
• Naveed Sattar on early, large-scale weight loss & the future of type 2 diabetes care, Laurent Azoulay on GLP-1s & the risk for optic neuropathy, plus a classic edition of "Rapid Exchange." · May 4, 2026 · 50 min
• Anna Kahkoska & Medha Munshi on improving care for T1D in older adulthood, Jennifer Sherr on the persistent burden of severe hypoglycemia in people with T1D despite technology use, plus a classic edition of "Rapid Exchange." · April 2, 2026 · 50 min
• Findings from the 2025 IDF Diabetes Atlas with Felix Teufel, Teplizumab & Type 1 Diabetes Therapies with Chantal Mathieu, and more! · March 2, 2026 · 1h 2m
• Untold Histories of Diabetes with Vanessa Heggie, Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes with Steven Kahn, and more! · February 5, 2026 · 45 min
• "How to Fix a Broken Healthcare System" with Seth Berkowitz, Marshall Chin, and Mariana Socal, a classic Rapid Exchange, and more! · January 6, 2026 · 49 min